A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
| Autor: | Robert M Manausa, Lala M. Dunbar, Derek M Tang |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Lipoglycopeptide medicine.drug_class vancomycin Antibiotics Review MRSA RM1-950 medicine.disease_cause telavancin chemistry.chemical_compound Telavancin Internal medicine medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Chemical Health and Safety business.industry General Medicine medicine.disease Surgery Penicillin Clinical trial Pneumonia chemistry Staphylococcus aureus Vancomycin Therapeutics. Pharmacology business Safety Research medicine.drug |
| Zdroj: | Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 1, Pp 235-244 (2008) Therapeutics and Clinical Risk Management |
| ISSN: | 1178-203X |
| Popis: | Lala M Dunbar1, Derek M Tang2, Robert M Manausa11Louisiana State University Health Sciences Center, New Orleans, USA; 2Tulane University School of Medicine, USAAbstract: Telavancin is a novel antibiotic being investigated for the treatment of serious infections caused by Gram-positive bacteria, including complicated skin and skin structure infections (cSSSI) and pneumonia. This once-daily intravenous lipoglycopeptide exerts rapid bactericidal activity via a dual mechanism of action. It is intended for use to combat infections caused by Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant and vancomycin-intermediate strains of S. aureus (MRSA and VISA, respectively). Vancomycin is the current gold standard in treating serious infections caused by Gram-positive bacteria, especially MRSA. In recent clinical trials, telavancin has shown excellent efficacy in phase II and III multinational, randomized, double-blinded studies of cSSSI. In the phase II FAST 2 study, which compared telavancin 10 mg/kg intravenously q 24 h vs standard therapy (an antistaphylococcal penicillin at 2 g IV q 6 h or vancomycin 1 gm IV q 12 h), the clinical success rate in the telavancin-treated group was 96% vs 94% in the standard therapy group. In two identical phase III trials comparing telavancin versus vancomycin at the doses of the FAST 2 study for cSSSI, the clinical cure rates were 88.3% and 87.1%, respectively. Two additional phase III clinical trials investigating telavancin for use in hospital-acquired pneumonia, caused by Gram-positive bacteria are currently ongoing. Telavancin is currently under regulatory review in both the United States and Europe for the indication of treatment of cSSSI.Keywords: telavancin, vancomycin, MRSA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|